Identification of TRA‐1‐60‐positive cells as a potent refractory population in follicular lymphomas
Open Access
- 11 November 2018
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 110 (1) , 443-457
Abstract
Despite receiving rituximab‐combined chemotherapy, follicular lymphoma (FL) patients often suffer tumor recurrence and understand that the cause of relapse in FL would thus significantly ameliorate the tumor therapeutics. In the present study, we show that TRA‐1‐60‐expressing cells are a unique population in FL, converge to the conventional stem cell marker Oct3/4 and ALDH1‐positive population, and resist current B‐lymphoma agents. TRA‐1‐60 expression was observed in scattered lymphoma cells in FL tissues only as well as in resting B‐lymphocytes inside germinal centers. Retrospective comparison between recurrent and cognate primary tissues showed that the number of TRA‐1‐60‐positive cells from rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R‐CHOP)‐treated FL had increased relative to primary tissue, a finding corroborated by assays on different rituximab‐treated FL cell lines, FL‐18 and DOHH2, wherein TRA‐positive cell numbers increased over 10‐fold compared to the untreated sample. Concordantly, scanty TRA‐1‐60‐positive FL‐18 cells implanted s.c. into mice evinced potent tumor‐initiating capacity in vivo, where tumors were 12‐fold larger in volume (P = 0.0021 < 0.005) and 13‐fold heavier in weight (P = 0.0015 < 0.005) compared to those xenografted from TRA‐negative cells. To explain these results, gene expression profiling and qPCR analysis indicated that TRA‐1‐60‐positive cells defined a distinct population from that of TRA‐negative cells, with upregulation of multiple drug transporters and therapeutic resistance genes. Hence, TRA‐1‐60‐expressing cells in FL are considered to be vigorously intractable against conventional therapeutic agents, which may explain its refractory recurrence.Keywords
Funding Information
- Japan Society for the Promotion of Science (16K15245, 24790350)
This publication has 28 references indexed in Scilit:
- Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate CancerPLOS ONE, 2011
- Tumorigenic Potential of Mononucleated Small Cells of Hodgkin Lymphoma Cell LinesThe American Journal of Pathology, 2010
- Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cellsNature Biotechnology, 2009
- Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphomaNature, 2009
- PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like CellsCell Stem Cell, 2009
- Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal regionNature Biotechnology, 2007
- Strategies and New Developments in the Generation of Patient-Specific Pluripotent Stem CellsCell Stem Cell, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell linesBlood, 2001